Loading company…
SUNGEN develops antibody drugs and other biologic candidates for several disease areas.
Founded in 2018 and based in Beijing, China, SUNGEN develops large-molecule biopharmaceuticals, including antibody drugs and early-stage biologic candidates for oncology, autoimmune and cardiovascular conditions. It works with medical institutions and pharmaceutical companies on drug discovery and development. In December 2025, Beijing Hotgen Biotech Co., Ltd. agreed to acquire a minority stake for CNY 381.6 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in